As AbbVie’s best-selling Humira faces oncoming biosimilar competition, the drug maker is developing a new innovator product that could help it retain a hold on the market; new results from 3 phase 3 clinical trials show AbbVie’s investigational interleukin-23 inhibitor, risankizumab, to be more effective than adalimumab (Humira) or ustekinumab (Stelara) in patients with moderate-to-severe plaque psoriasis.
As AbbVie’s best-selling Humira faces oncoming biosimilar competition, the drug maker is developing a new innovator product that could help it retain a hold on the market; new results from 3 recent phase 3 clinical trials show AbbVie’s investigational interleukin-23 (IL-23) inhibitor, risankizumab, to be more effective than adalimumab (Humira) or ustekinumab (Stelara) in patients with moderate-to-severe plaque psoriasis.
All 3 trials met the co-primary endpoints of at least a 90% improvement in symptoms in the Psoriasis Area and Severity Index (PASI 90), and a score of clear or almost clear as measured by the static Physician Global Assessment (sPGA) scale at week 16, compared with placebo or adalimumab.
“What is particularly exciting is the number of patients who achieved high rates of skin clearance in these 3 head-to-head clinical trials,” said Michael Severino, MD, AbbVie’s executive vice president of research and development and chief scientific officer. “Risankizumab has the potential to provide a meaningful new treatment option for people living with psoriasis.”
Two of the trials reported [ultIMMA-1 (n = 506) and ultIMMa-2 (n= 491)] were replicate phase 3 trials evaluating the safety and efficacy of risankizumab (150 mg) compared with placebo or ustekinumab (45 mg or 90 mg based on patient weight). The third trial, IMMvent, studied risankizumab versus adalimumab (n = 605).
AbbVie notes that phase 3 trials of risankizumab in psoriasis are ongoing, and the drug is also being investigated to treat Crohn’s disease and psoriatic arthritis. Future trials are planned to investigate risankizumab in ulcerative colitis.
Risankizumab Versus Placebo or Ustekinumab (ultIMMA-1 and ultIMMa-2)
After 16 weeks of treatment, 75% of patients receiving risankizumab in both studies achieved a response of PASO 90, compared with 5% of patients receiving placebo in ultIMMa-1 and 2% receiving placebo in ultIMMa-2. These response rates were significantly greater than the ustekinumab PASI 90 response rates of 42% (ultIMMa-1) and 48% (ultIMMa-2). Additionally:
Risankizumab Versus Adalimumab (IMMvent)
IMMvent data showed that patients receiving risankizumab had significantly higher response rates than those receiving adalimumab:
In the second phase of IMMvent (week 16 to 44), patients with a response to adalimumab of PASI 50 to less than PASI 90 at week 16 were re-randomized to either switch to risankizumab or continue adalimumab. Of these patients:
“In this trial, 4 out of 5 patients achieved clear or almost clear skin with risankizumab at week 16,” noted Kristian Reich, MD, the principal investigator for IMMvent. He said the results support previous findings that risankizumab has the potential to address unmet needs for patients with psoriasis.
No new safety signals were detected across the phase 3 program for plaque psoriasis. In ultIMMa-1 and ultIMMa-2, serious adverse events through week 16 occurred in 2% of patients on risankizumab in both studies, compared with 3% and 1% of patients on placebo and 8% and 3% of patients on ustekinumab, respectively.
Through 1 year, SAEs in the ultIMMa-1 and ultIMMa-2 trials occurred in 8% and 7% of patients in the continuous risankizumab group, respectively, compared with 11% and 7% of patients treated continuously with ustekinumab. One patient in ultIMMa-2 receiving risankizumab died from a sudden cardiac arrest 101 days after the last dose of study drug; a second patient receiving risankizumab died 161 days after the last dose (cause of death is unknown). Both patients had a history of cardiovascular risk factors. There were no deaths reported among patients in ultIMMa-1.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).